Priority review pathway

As part of the Government's response to the Review of Medicines and Medical Devices Regulation (MMDR review), the TGA has implemented a priority pathway for the registration of novel prescription medicines for Australian patients.

The priority pathway provides a formal mechanism for faster assessment of vital and life-saving prescription medicines. The target timeframe of 150 working days is up to three months shorter than the standard prescription medicines registration process.

For details read priority review pathway: prescription medicines.